Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | Chief Operating Officer | October 15, 2025 | October 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date October 15, 2025 · Filed October 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,250 |
Reported balance
After 2025-10-15 transaction · row 1
1 source rowRow 1 · 2025-10-15 · Exercise / conversion · Acquired 1,250 · Balance 1,250 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2034-07-20 | Direct | 40,052 |
Reported balance
After 2025-10-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-15 · Exercise / conversion · Disposed 1,250 · Balance 40,052 F1: 1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2025 Filed Oct 16, 2025 18:12 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | Exercise / conversionStock option (right to buy) · Derivative | 1,250 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001193125-25-241643 · ownership.xml · derivative · entry 2 Jones Bryan · CIK 0002045615 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,052 Underlying: Common Stock · 1,250 shares Expires 2034-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 18:12 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | Exercise / conversionCommon Stock | 1,250 | $4.24 | $5,300.00 |
DisclosureSEC source: 0001193125-25-241643 · ownership.xml · nonDerivative · entry 1 Jones Bryan · CIK 0002045615 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:05 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 122,033 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086139 · ownership.xml · derivative · entry 1 Jones Bryan · CIK 0002045615 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,033 Underlying: Common Stock · 122,033 shares Expires 2035-06-11 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 11, 2026, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.